CVS Health ends in green for its seventh straight session

Shares of CVS Health (NYSE:CVS) ended higher on Thursday, recording gains for its seven consecutive sessions and gaining over 13% over that period.

The healthcare services company rose 0.46% to end the Thursday trading session at $60.98. Since the start of the year, CVS Health has fallen about 23%, underperforming the broader S&P index.

Looking at Seeking Alpha's Quant ratings, CVS had a Hold rating with a score of 3.20 out of 5. The company received an A+ for profitability and a D- for its growth prospects. The stock got an A for valuation.

Turning to the Wall Street community, about 15 sell-side analysts surveyed in the last 90 days rated CVS as a Buy or higher. Meanwhile, another 13 analysts rated the company as a Hold or lower.

Seeking Alpha analysts generally saw the company as a Buy. The Insiders Forum, SA analyst, endorsed the company as a Hold, commenting that the company is facing higher medical benefit ratios in its Medicare Advantage plans and is ineligible for full-level quality bonuses in FY24.